Phospho-MEK7 (Ser271 + Thr275)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产品编号xy- 3277R
英文名称Phospho-MEK7 (Ser271 + Thr275)
中文名称磷酸化丝裂原活化蛋白激酶MKK7抗体
别 名MEK7 (phospho S271 + T275); p-MEK7 (phospho S271 + T275); MEK7 (phospho S271 + T275); MEK7 (phospho Ser271 + Thr275); c-Jun N-terminal kinase kinase 2; Dual specificity mitogen activated protein kinase kinase 7; Dual specificity mitogen-activated protein kinase kinase 7; JNK activating kinase 2; JNK kinase 2; JNK-activating kinase 2; Jnkk 2; Jnkk-2; Jnkk2; MAP kinase kinase 7; MAP2K7; MAPK/ERK kinase 7; MAPKK 7; MAPKK-7; MAPKK7; MEK 7; Mitogen Activated Protein Kinase kinase 7; MKK 7; MKK-7; MKK7; MP2K7_HUMAN; PRKMK 7; PRKMK-7; PRKMK7; Sek 2; Sek-2; Sek2.
说 明 书100ul
产品类型磷酸化抗体
研究领域肿瘤 信号转导 细胞凋亡 转录调节因子 激酶和磷酸酶 细胞膜受体
抗体来源Rabbit
克隆类型Polyclonal
Phospho-MEK7 (Ser271 + Thr275)抗体交叉反应 Human, Mouse, Rat, Dog, Pig, Cow,
产品应用WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 Flow-Cyt=1μg /Test IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量47kDa
细胞定位细胞核 细胞浆
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated synthesised phosphopeptide derived from human MKK7 around the phosphorylation site of Ser271/Thr275:VD(p-S)KAK(p-T)RS
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Phospho-MEK7 (Ser271 + Thr275)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产品介绍background:
The protein encoded by this gene is a dual specificity protein kinase that belongs to the MAP kinase kinase family. This kinase specifically activates MAPK8/JNK1 and MAPK9/JNK2, and this kinase itself is phosphorylated and activated by MAP kinase kinase kinases including MAP3K1/MEKK1, MAP3K2/MEKK2,MAP3K3/MEKK5, and MAP4K2/GCK. This kinase is involved in the signal transduction mediating the cell responses to proinflammatory cytokines, and environmental stresses. Multiple alternatively spliced transcript variants encoding distinct isoforms have been found, but only one transcript variant has been supported and defined. [provided by RefSeq, Jul 2008].
Function:
Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Essential component of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. With MAP2K4/MKK4, is the one of the only known kinase to directly activate the stress-activated protein kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 and MAP2K7/MKK7 both activate the JNKs by phosphorylation, but they differ in their preference for the phosphorylation site in the Thr-Pro-Tyr motif. MAP2K4/MKK4 shows preference for phosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thr residue. The monophosphorylation of JNKs on the Thr residue is sufficient to increase JNK activity indicating that MAP2K7/MKK7 is important to trigger JNK activity, while the additional phosphorylation of the Tyr residue by MAP2K4/MKK4 ensures optimal JNK activation. Has a specific role in JNK signal transduction pathway activated by proinflammatory cytokines. The MKK/JNK signaling pathway is also involved in mitochondrial death signaling pathway, including the release cytochrome c, leading to apoptosis.
Subunit:
Interacts with isoform 1 of VRK2. Interacts (via its D domain) with its substrates MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. Interacts (via its DVD domain) with MAP3Ks activators like MAP3K5/ASK1 and MAP3K1/MEKK1. Interacts with MAPK8IP1/JIP1, MAPK8IP2/JIP2 and MAPK8IP3/JIP3 scaffold proteins. Interacts with RASSF7, the interaction promotes phosphorylation.
Subcellular Location:
Nucleus. Cytoplasm.
Tissue Specificity:
Ubiquitous; with highest level of expression in skeletal muscle. Isoform 3 is found at low levels in placenta, fetal liver, and skeletal muscle.
Post-translational modifications:
Activated by phosphorylation on Ser-271 and Thr-275 by MAP kinase kinase kinases (MAP3Ks).
Similarity:
Belongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.
Contains 1 protein kinase domain.
Gene ID:
5609
Phospho-MEK7 (Ser271 + Thr275)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“Y”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
Phospho-MEK7 (Ser271 + Thr275)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
IgG经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 Cystatin C 胱抑素C/半胱氨酸蛋白酶抑制剂C单克隆抗体
合格 Cystatin C 胱抑素C/半胱氨酸蛋白酶抑制剂C单克隆抗体
合格 GSK-3 Beta 糖原合酶激酶-3β单克隆抗体
合格 Ubiquitin 泛素蛋白单克隆抗体
合格 合格 Actin, alpha skeletal muscle 肌动蛋白α1抗体
合格 LC3A 自噬微管相关蛋白轻链3单克隆抗体
合格 Epsilon Tubulin ε-微管蛋白单克隆抗体
合格 Beclin 1 Bcl-2同源结构域蛋白单克隆抗体
合格 Beclin 1 Bcl-2同源结构域蛋白单克隆抗体
合格 Beclin 1 Bcl-2同源结构域蛋白单克隆抗体
合格 MMP2 基质金属蛋白酶2单克隆抗体
合格 Tau 微管相关蛋白单克隆抗体
合格 ERK1 丝裂原活化蛋白激酶1单克隆抗体
合格 Phospho-Smad3 (Ser425) 磷酸化细胞信号转导分子SMAD3单克隆抗体
合格 TTR/Prealbumin 转甲状腺素蛋白/前白蛋白单克隆抗体
合格 TTR/Prealbumin 转甲状腺素蛋白/前白蛋白单克隆抗体
合格 Acetyl NF kB P65 (Lys314/Lys315) 乙酰化细胞核因子(K314/K315)单克隆抗体
合格 CEA 癌胚抗原抗体
合格 合格 YWHAZ 小鼠抗14-3-3蛋白zeta/delta单克隆抗体